Search

Background: Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases.Methods: A randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18thApril till 18thMay. 50patients received favipiravir 3200mg at day1 followed by 600mg twice (day2-day10). 50patients received hydroxychloroquine 800mg at day1 followed by 200mg twice (day2- 10) and oral oseltamivir 75mg/12hour/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital.Results: Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p=0.7). Four patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Conclusion: Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.